106 related articles for article (PubMed ID: 32011525)
1. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma.
Itchins M; Chua TC; Arena J; Jamieson NB; Nahm CB; O'Connell RL; Bailey EA; Schembri GP; Gill AJ; Kneebone A; Hruby G; Mittal A; Pavlakis N; Clarke SJ; Samra JS
Pancreas; 2020 Feb; 49(2):224-229. PubMed ID: 32011525
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of
Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
[TBL] [Abstract][Full Text] [Related]
3. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Itchins M; Arena J; Nahm CB; Rabindran J; Kim S; Gibbs E; Bergamin S; Chua TC; Gill AJ; Maher R; Diakos C; Wong M; Mittal A; Hruby G; Kneebone A; Pavlakis N; Samra J; Clarke S
Eur J Surg Oncol; 2017 Sep; 43(9):1711-1717. PubMed ID: 28688722
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.
Ikenaga N; Nakata K; Hayashi M; Nakamura S; Abe T; Ideno N; Murakami M; Fujimori N; Fujita N; Isoda T; Baba S; Ishigami K; Oda Y; Nakamura M
J Gastrointest Surg; 2023 Feb; 27(2):337-346. PubMed ID: 36652179
[TBL] [Abstract][Full Text] [Related]
5. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
Choi M; Heilbrun LK; Venkatramanamoorthy R; Lawhorn-Crews JM; Zalupski MM; Shields AF
Am J Clin Oncol; 2010 Jun; 33(3):257-61. PubMed ID: 19806035
[TBL] [Abstract][Full Text] [Related]
6. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer.
Carlson DM; Abdelrahman AM; Adjei Antwi SK; Tomlinson JL; Trivedi K; Karbhari A; Patnam Gopal Chetty N; Halfdanarson TR; Goenka AH; Truty MJ
J Am Coll Surg; 2024 Jul; 239(1):9-17. PubMed ID: 38445645
[TBL] [Abstract][Full Text] [Related]
7. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.
Wang ZJ; Behr S; Consunji MV; Yeh BM; Ohliger MA; Gao K; Ko AH; Cinar P; Tempero MA; Collisson EA
AJR Am J Roentgenol; 2018 Nov; 211(5):1010-1019. PubMed ID: 30063366
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
9. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
[TBL] [Abstract][Full Text] [Related]
11. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
12. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
13. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
14. Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[
Tabata K; Nishie A; Shimomura Y; Isoda T; Kitamura Y; Nakata K; Yamada Y; Oda Y; Ishigami K; Baba S
Clin Radiol; 2022 Jun; 77(6):436-442. PubMed ID: 35410786
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
[TBL] [Abstract][Full Text] [Related]
16. Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.
Karbhari A; Mosessian S; Trivedi KH; Valla F; Jacobson M; Truty MJ; Patnam NG; Simeone DM; Zan E; Brennan T; Chen H; Kuo PH; Herrmann K; Goenka AH
PLoS One; 2023; 18(11):e0294564. PubMed ID: 38011131
[TBL] [Abstract][Full Text] [Related]
17. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
Pergolini I; Crippa S; Salgarello M; Belfiori G; Partelli S; Ruffo G; Pucci A; Zamboni G; Falconi M
Dig Liver Dis; 2018 Jan; 50(1):84-90. PubMed ID: 29017830
[TBL] [Abstract][Full Text] [Related]
18. SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly Lower Lymph Node Metastasis Rates.
Kassardjian A; Wang HL
Pancreas; 2020 Oct; 49(9):1153-1160. PubMed ID: 32897998
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
